The volume of high throughput screening data has considerably increased since the begin of the automated biochemical and cell-based assays era. This information rich data source provides tremendous repurposing opportunities for data mining. It was recently shown that biochemical or cell-based assay results can be compiled into so called high-throughput fingerprints (HTSFPs) as a new type of descriptor describing molecular bioactivity profiles which can be applied in virtual screening, iterative screening, and target deconvolution. However, so far studies around HTSFPs and machine learning have mainly focused on predicting the outcome of molecules in single highthroughput assays and no one has reported the modelling of compounds' biochemical assay activities towards a panel of target proteins. Therefore, there is a need for a detailed analysis of the performance of predictive models built with HTSFPs with respect to models built with more widely used structural descriptors both in terms of hit identification and of scaffold hopping potentials. In this article, in-house HTSFPs were built and combined with multi-task deep learning and support vector machine methods to build compound activity predictive models. Performances of HTSFP models were compared to the performances of models built with the conventional structural descriptors ECFPs. Moreover, we investigated the effect of high throughput screening false positives and negatives on the performance of deep learning models. Our results showed that the two fingerprints yielded in similar performances and in diverse hits with very little overlap, thus demonstrating the orthogonality of bioactivity profile based descriptors with structural descriptors. Therefore, modelling compound activity data using ECFP together with HTSFPs increases the scaffold potential of the predictive models.
Introduction
One of the most common assumptions made in cheminformatics is that molecules with similar structures share similar biological properties. 1 Following this principle, molecular structural descriptors were extensively used in building QSAR models. 2 However, the similarity principle has largely limited the potential of identifying novel chemical structures using predictive models based on structural descriptors. It is a dilemma that modelling with structural descriptors is quite useful in building predictive models, while it is in general difficult to discover novel chemotypes beyond the ones present in the training set. To address that problem, the concept of "bioactivityprofile fingerprints" was put forward. In 1989, a team from NIH developed an algorithm to analyze "cell-response-fingerprints" toward NCI cancer-cell lines. 3 Most notably, the method revealed interesting patterns in the activity of drug molecules on the 60 NCI cancer cell lines, which suggested that the biological profiles can provide insights in the mechanism of action (MoA) of drug molecules. This in turn, has paved the way for using biological profile descriptors in drug
MoA predictions and target deconvolutions. Other efforts applying the same concept appeared shortly after, researchers combined neuronal network and cell-response-fingerprints (based on NCI cancer cell lines) to predict the MoA of cancer drugs. 4 Similar fingerprints encoding cell-growth inhibition over the NCI cancer cell lines were used in conjunction with structural descriptors to search for cancer drug candidates insensitive to intact p53 suppressor gene function. 5 Most importantly, with this work the authors proposed that it is possible to identify novel candidate drugs inducing desirable cellular effects based on their bioactivity profiles. A similar workflow was implemented in the "biospectras" analysis, which allowed the identification of new agonist and antagonist chemotypes for dopamine receptors. 6 Furthermore, biospectras were used to understand undesired secondary drug effects. 7 More recently, the concept of cell-response fingerprint was used to develop the so-called "bioactivity profile similarity search" approach, a method capable of identifying targets of uncharacterized bioactive compounds. 8 Target identification using bioactivity profiles was later re-visited and applied to a battery of cell-based and biochemical screening assays to build a novel bioactivity based fingerprint. 9 Interestingly, in this work the MoA of novel antimalaria compounds was identified from bioactivity fingerprints made from cell-based and biochemical assays even though it did not encode any assay related to malaria. This result strongly suggests that bioactivity profile fingerprints contain useful information even for targets outside the proteome for which they encode.
With the advent of high-throughput screening (HTS) technologies in the early 90s, where typically millions of compounds can be screened within a few weeks, 10 the large amount of accumulated biochemical and cell-based HTS data in pharmaceutical industry became a valuable source for building the so called HTSFPs to characterize compounds' bioactivity profile. In 2012, Petrone et al., published an elegant study showing that HTSFP built over 195 HTS assays (biochemical and cell-based) can be used to identify MoAs. 11 Along similar lines, HTSFPs also contributed to different studies identifying the MoAs of drugs and natural products or identifying compounds with similar phenotypic profiles. [12] [13] Multiple studies have shown that compounds with similar bioactivity profiles can have different structures. 6, 11, [14] [15] where identifying a diverse set of hit compounds from a query structure is desired. [16] [17] Due to the availability of HTS data in most large pharmaceutical companies, it is not surprising 22 In a more recent article, Cabrera and Petrone, proposed a desirability function for selecting HTS assays with optimal informative content for HTSFP definitions. 23 Even though most HTS data is in the industry, and is not publicly accessible, efforts have also been put into the evaluation of publicly accessible HTSFPs build upon 243 HTS assays (biochemical and cell-based) deposited in PubChem for hit expansion. 24 During the last decade, extraordinary success has been witnessed in deep learning technologies specifically in areas like computer vision 25 , language processing 26 and speech recognition. 27 Various deep learning technologies, but especially the multi-task learning strategy has been applied in Cheminformatics research. In the multi-task machine learning scenario, one aims to utilize data of multiple targets to build one predictive model capable of modelling multiple tasks simultaneously. 28 The rationale of such an approach is that the modelling of tasks with few data points can be assisted by shared information of other tasks. [29] [30] The chemogenomics modelling, which aims to predict the activity of compounds regarding a panel of target proteins using a very sparse endpoint data matrix, particularly suits the multi-task deep learning approach. 31 So far, the application of HTSFPs is mainly limited in building single target models, while the machine learning in the cheminformatics field is shifting towards new deep learning technologies in a multitask modeling setting. [31] [32] [33] [34] In the present study, we examined the utility of HTSFPs and combined it with deep neural network methods to build multi-task models. HTSFPs' model performance was compared with the traditional structural descriptor ECFPs' using single-task machine learning method.
METHODS
Generation of high-throughput screening fingerprints. In this study, we investigated the utility of high-throughput fingerprints (HTSFPs) for predicting compound activities for a panel of targets.
The rationale behind the idea is that HTSFPs, composed by the outcomes of a compound towards a series of primary high-throughput screening (HTS) assays, represent the biological profile of a compound and could be used to predict its activity against other targets. HTS data was collected from historical primary screening campaigns performed at AstraZeneca over recent years: a collection of 1,250 HTS assays. From those assays, we extracted all the records in which the compounds were screened at the most commonly tested concentration, 10µM. The set of HTS assays was trimmed down to a list of 503 assays by discarding every assay in which less than
200,000 compounds were tested. This set of 503 assays constituted the basis for the construction of each HTSFP, such that each fingerprint compiled the outcomes of one compound in all the 503 assays. To avoid compounds with too few HTS experimental data points in their fingerprint, we kept only the compounds tested in 406 assays out of the 503 panel assays (roughly 80% of the assays). Following this approach, we could build a dataset of HTSFPs for 57,124 compounds. Our fingerprints encode whether the compound was Active or Inactive in each of the assays as a binary vector. Even though in others studies, the values in their fingerprint were set according to activity readout Z-scores, 11, 13, 24 we have set our fingerprint bits as binary values according to high quality activity flags set by expert biologists running the assays. Our choice was also motivated by the fact that our HTS assays were rarely annotated with Z-scores and that activity readouts usually did not follow normal distributions. We arbitrarily set all missing values (i.e. compounds not tested in an assay) to Inactive assuming that one compound is more likely to be inactive than active in any given HTS assay, similar to what was reported by Riniker et al. 19 Other methods using HTSFPs to measure compound's similarity without consideration HTSFP missing bits were described here. where the goal is often to identify novel chemical entities which have not been seen in the training set, we made a cluster based splitting on the dataset so that every cluster always sits within the same fold and no cluster can spread across different folds. A cluster based split also avoids bias in the performance evaluation due to similar chemical series present in train and test sets. 38 The procedure can be described in the following steps: firstly, a structural clustering using the ECFP fingerprint (Ambit toolkit) and sphere-exclusion algorithm with threshold of 0.45 was carried out on the whole dataset; secondly, all clusters were randomly shuffled regardless of their size and split into three folds based on the new order. After the splitting, the size (i.e. the number of compound) of each fold was examined to see if the fold size was within the ± 35 compound threshold of the size of even distribution. The folding solution was kept if the criterion was met and the random shuffling process was repeated until 1000 valid folding solutions were found;
Lastly, for each valid folding solution, three different configurations of training and test sets (i.e.
two folds for training and one-fold for testing) were inspected to get the list of unique targets overlapping between training and test sets. The folding solution with the largest overlapping target list was selected as the final folding solution, it contained 340 targets in each test set.
Building of target prediction models. Two different machine learning algorithms were used to study the performance of the HTSFPs on compound activity predictions. Support vector machine (SVM) method was used for building single-task compound activity prediction models, whereas the deep neural network (DNN) algorithm was used for multi-task models. These represent two different machine learning concepts, where single-task models are built with individual target data and multi-task models are built by simultaneously using the data of multiple targets. Our main goal was to compare the model performance for traditional structural fingerprints (ECFP) and the biological profile based (HTSFP) descriptors in both model building scenarios. For both machine learning algorithms, we first performed hyperparameter grid searches to find optimal hyperparameters and then used the selected hyperparameters to train classification models with a normal cross-validation scheme throughout the study.
We built SVM models with radial basis function kernel from the scikit-learn package. 39 Training and test sets were split with a ratio of 2:1 as described above. Performance evaluation. A model's overall performance was assessed by the mean ROC-AUC score averaged over all predicted targets. For metrics based on predicted classifications, we determined target-specific score thresholds based on best F1-score obtained from predictions made on the training set. 42 The thresholds were then applied to the predictions made on the test set to obtain predicted classifications and recall scores. In addition, we assessed the chemical novelty of the predicted actives with respect to active molecules in the training set. To do so, we counted the number of novel molecular and topological scaffolds 43 present within the 10% best scored true positives. A true positive scaffold was considered novel if it was not seen in the training set actives.
Molecular scaffolds and topological scaffolds were extracted from the SMILES of the molecules using the MurckoScaffoldSmiles and MakeScaffoldGeneric methods respectively, both available in the MurckoScaffold module of RDKit. 44 Lastly, we evaluated the chemical similarity of the active molecules which were correctly predicted with respect to the actives of the training set. For each target, we reported the nearest neighbors' chemical similarity (Tanimoto coefficient, with ECFPs).
RESULTS AND DISCUSSION
Overview of HTSFP and target activity dataset. We built a dataset from historical HTS campaigns accumulated over the years at AstraZeneca. The dataset is composed of 52,938
compounds all annotated by their outcome in 406 to 503 HTS assays. The prediction endpoints of these compounds were then fetched from secondary screenings dose-response data of
AstraZeneca. This resulted in a set of 52,938 compounds with activities towards a panel of 340 target proteins.
The number of compounds tested per target protein was highly imbalanced ( Figure 1A ). There are roughly two blocks of targets: 140 targets tested with less than 7% of the compounds (less than 3,705 compounds), and 200 targets tested with more than 7% of the compounds. Among the latter targets, 171 targets were tested with more than 75% of the compounds (more than 39.7k compounds). In terms of fraction of active compounds for each target, the trend was reversed with respect to the proportion of compounds per target. Targets having smaller number of compounds tend to have higher fraction of active compounds than the target having larger number of compounds.
From the perspective of the HTSFPs, each compound was annotated with the activity flags of 424.7 HTS assays on average, thus leaving about 16.5% of the [HTSFP × compound] matrix empty, which were all arbitrarily set to Inactive. In total, the [HTSFP × compound] matrix had a total of 98.8% of the elements set to Inactive (Figure 1B) , which is on par to ECFP6 folded into across our dataset and a maximum of 6,958 Active compounds (18.2% of the dataset). It is important to note that 47 assays had no Active at all among the tested compounds, thus having no impact in the modelling task. Consequently, modelling studies with HTSFPs considered only the 456 assays that had at least one Active bit. 
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were assessed by measuring the ROC-AUC value on the test set.
ROC-AUC performances in predicting compound activities towards the 209 internal targets were significantly better when modelling the activities with HTSFP than with ECFP ( Figure S3 ).
However, this high performance only highlights correlation between HTS primary screening data and dose-response secondary screenings data which has a low predictive value. In the remainder of the study we focused on the performance of our models in predicting the 131 external targets.
For these targets, overall prediction performance of the HTSFP models was still better than ECFP models but the difference to ECFP models was smaller (Figure 2A, B which is in line with a previous report which compared the performance of ECFP and HTSFP descriptors using the Naïve Bayes method. 22 It is also interesting to note that the multi-task DNN models perform better than single task models in general, thus suggesting that the learning process for a given target can be augmented by the data of other related targets. than the structural descriptors. 11, 19, 22, 24 The main explanation for this is that bioactivity profiles are not necessary correlated to structural similarity, as similar compounds can have different bioactivity profiles and dissimilar compounds can have similar bioactivity profiles. For instance,
HTSFPs have shown their utility in iterative screening exercises by retrieving hits that differed structurally to predictions made by structural descriptors. 22 Moreover, HTSFPs built upon public datasets have also shown their utility in retrieving hits that are structurally diverse and distinct to hits found with structural descriptors. 24 All these together make HTSFPs a very attractive descriptor for hit discovery. Here, we would like to investigate if the superior performance on scaffold hopping can also be demonstrated on our in-house HTSFPs and particularly when they are combined with the DNN algorithm. To evaluate the scaffold hopping potential, we characterized the chemical novelty of the correctly predicted active molecules with respect to the active compounds of the training set. To do so, we expressed chemical novelty as the number of molecular scaffolds found in correctly predicted active molecules but not seen in the active molecules of the training set. In that sense, we considered a scaffold as being novel only if it did not appear in the training set. We have seen in the previous section that the performance of the models varies depending on the used molecular descriptor. Consequently, it is difficult to make a fair comparison between the number of correctly predicted active molecules retrieved by HTSFP and ECFP models. To address this problem, we limited this analysis to the 10% best scored active molecules based on each target. This allowed us to compare the chemical novelty present in the same number of true positives for each descriptor (Figure 3) . Furthermore, this choice was motivated by the fact that our models correctly classified the majority of the 10% best scored active molecules with the defined target-specific score thresholds (mean recalls were 0.38 ± 0.13 and 0.25 ± 0.15 for DNN-HTSFP and DNN-ECFP; 0.35 ± 0.13 and 0.40 ± 0.14 for SVM-HTSFP and
SVM-ECFP).
On average, the test set contained 32.6 active molecular scaffolds per target out of which 28.9 were novel scaffolds ( Figure S4 ). In terms of topological scaffolds, we there was 27.0 active topological scaffolds per target, out of which 19.6 were novel. Most of the scaffolds of the test set are novel because we have split the data based on a structural clustering (see methods sections). It is interesting to note that, the overlap of novel scaffold between targets is smaller for SVM models. When we pooled the novel scaffolds found for all the targets together, we obtained a total Figure 6A shows that adding noise in the HTSFP marginally impacts the predictive performance of the DNN models, which highlights the robustness of DNN models to HTS false positives.
In the second experiment, we randomly removed active bits (i.e. false HTS negatives) in the HTSFP and evaluated the resulting DNN models based on ROC-AUC obtained for the 131 external targets. The removal of active bits in the HTSFPs has a more drastic impact on the prediction of DNN models, with an almost complete loss in performance upon annulation of 90 to 95% of the active bits ( Figure 6B) . Nevertheless, turning off up to 50% the active bits in the HTSFP led to a loss in performance of only 25%, which suggests that a subset of the HTS assays encoded in the HTSFPs carries most of the predictive value. Consequently, it could be valuable to reduce the length of the HTSFP by carefully selecting a subset of HTS assays in order to increase HTSFP datasets, as was recently suggested elsewhere. 23 Furthermore, these results are similar to conclusions made in a study of the impact of missing data in the performances of multi-task models. 47 However, our analysis shows that the loss of performance is similar when reducing the signal contained within descriptors (loss is marginal until a threshold, after which loss is drastic). 
Conclusion
We used in-house HTSFP descriptors for predicting compound activities against a set of external target proteins with multi-task deep neural network models and single task SVM models. The prediction quality and the scaffold hopping capability of HTSFPs was carefully compared -target by target -and compared to the widely used ECFP fingerprint descriptors. Our analyses demonstrated that, despite the smaller size of HTSFPs, the quality of the predictions made with HTSFP models were at least as good as the prediction of ECFP models for targets external to the HTSFP assay panel. We also specifically characterized the scaffold hopping potential of the two descriptors against each other with a detailed analysis of the composition of the top predicted active molecules. The results have shown that HTSFP and ECFP predict similar numbers of novel scaffolds, with very little overlap. Consequently, our observations showed that using both descriptors doubles the chemical novelty of identified hits. Furthermore, we also compared the structural similarity of identified hits in the test set against true positives in the training set. Hits retrieved by the HTSFP models were in general the most novel with respect to the active compounds seen in the training set, which highlights the interesting scaffold hopping potential of HTSFP. Lastly, with the concern of robustness of the HTSFP model, we investigated how the level of noise in the HTSFPs could impact DNN's predictions. We observed that performance of DNN models is marginally affected when randomly doubling the number of active bits in the HTSFP (i.e. false positive hits) or by randomly deleting a quarter of the active bits in the HTSFP (i.e. false negatives). A drawback with HTSFP is that they can't be generated for new compounds in a compound collection since they haven't been screened in many assays yet. Nevertheless, there is still value in repurposing HTS data into compound's biological profile to complement the molecular structure information, especially for hit identification with machine learning algorithms. Figure S1 . Nested-cross validation learning curves of DNN with ECFP. 
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